What's in Zhejiang Teruisi Pharmaceutical Inc.'s pipeline?

Zhejiang Teruisi Pharmaceutical Inc. has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Zhejiang Teruisi Pharmaceutical Inc.'s portfolio?

Top competitors by shared drug class: Barnes Retina Institute, Bio-Thera Solutions, Centus Biotherapeutics Limited, Cipla BioTec Pvt. Ltd., Eli Lilly and Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zhejiang-teruisi-pharmaceutical-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zhejiang Teruisi Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zhejiang Teruisi Pharmaceutical Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
China-approved Bevacizumab	China-approved Bevacizumab	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)	Oncology
TRS003	TRS003	phase 3

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Barnes Retina Institute · 1 shared drug class
Bio-Thera Solutions · 1 shared drug class
Centus Biotherapeutics Limited · 1 shared drug class
Cipla BioTec Pvt. Ltd. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Grewal Eye Institute · 1 shared drug class
Hanny Al-Samkari, MD · 1 shared drug class
Institut de Recherches Internationales Servier · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhejiang Teruisi Pharmaceutical Inc.:

Cite this brief

Drug Landscape (2026). Zhejiang Teruisi Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhejiang-teruisi-pharmaceutical-inc. Accessed 2026-05-17.